According to Stryker Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 52.674. At the end of 2022 the company had a P/E ratio of 39.2.
Year | P/E ratio | Change |
---|---|---|
2022 | 39.2 | -22.37% |
2021 | 50.6 | -11.91% |
2020 | 57.4 | 52.25% |
2019 | 37.7 | 128.19% |
2018 | 16.5 | -70.88% |
2017 | 56.7 | 108.77% |
2016 | 27.2 | 11.66% |
2015 | 24.3 | -58.99% |
2014 | 59.3 | 109.23% |
2013 | 28.4 | 76.38% |
2012 | 16.1 | 12.87% |
2011 | 14.2 | -14.86% |
2010 | 16.7 | -7.34% |
2009 | 18.1 | 26.99% |
2008 | 14.2 | -52.62% |
2007 | 30.0 | 4% |
2006 | 28.9 | 3.91% |
2005 | 27.8 | -36.69% |
2004 | 43.9 | 11.97% |
2003 | 39.2 | -2.53% |
2002 | 40.2 | -4.98% |
2001 | 42.3 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Medtronic MDT | 32.0 | -39.33% | ๐ฎ๐ช Ireland |
Baxter BAX | 8.34 | -84.17% | ๐บ๐ธ USA |
Boston Scientific BSX | 83.7 | 58.87% | ๐บ๐ธ USA |
Edwards Lifesciences EW | 40.5 | -23.13% | ๐บ๐ธ USA |
Waters Corporation WAT | 30.3 | -42.46% | ๐บ๐ธ USA |
Integra LifeSciences IART | 28.5 | -45.80% | ๐บ๐ธ USA |
Smith & Nephew
SNN | 23.5 | -55.43% | ๐ฌ๐ง UK |
Owens & Minor
OMI | -21.7 | -141.13% | ๐บ๐ธ USA |
Hill-Rom HRC | N/A | N/A | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.